Time and Dates: 1 p.m.-5 p.m. August 3, 1995.

Place: National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, Atlanta, Georgia 30345.

Status: Closed.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to Program Announcements 328, 432, and 461, entitled Cooperative Agreements for Prevention Centers/National Center for Chronic Disease Prevention and Health Promotion—General Special Interest Projects, Panel Number 2.

The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463.

Contact Person for More Information: James E. Barrow, Deputy Director, Office of Surveillance and Analysis, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, m/s K30, Atlanta, Georgia 30345. Telephone 404/488–5269.

Dated: June 28, 1995.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–16514 Filed 7–5–95; 8:45 am]

BILLING CODE 4163–18–M

Food and Drug Administration

[Docket No. 95M–0179]

Summit Technology, Inc.; Premarket Approval of Excimed® UV200LA and SVS Apex (Formerly the OmniMed) Excimer Laser Systems

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by Summit Technology, Inc., Waltham, MA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the Excimed® UV200LA and the SVS Apex Excimer Laser Systems. After addressing the concerns of the Ophthalmic Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter on March 10, 1995, of the approval of the application.

DATES: Petitions for administrative review by August 7, 1995.

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Debra Y. Lewis, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2018.

SUPPLEMENTARY INFORMATION: On February 20, 1992, Summit Technology, Inc., Waltham, MA 02154, submitted to CDRH an application for premarket approval of the Excimed® UV200LA and the SVS Apex Excimer Laser Systems. The excimer laser in the two systems delivers pulses at 193 nanometers wavelength. The excimer laser is indicated for use in the following Phototherapeutic Keratectomy procedures which treat superficial pathology located in the anterior 100 microns of the cornea, where the proposed treatment area is at least 400 microns in thickness, and where other less invasive treatments have failed or are not possible, such as contact lens intolerance. This indication is limited to patients with decreased visual acuity or symptoms of pain and discomfort of sufficient severity to cause disability for the patients with any of the following conditions: (1) Superficial corneal dystrophies (granular, lattice, and Reis-Buckler's); (2) epithelial basement membrane dystrophy; (3) irregular corneal surfaces (secondary to Salzmann's degeneration, keratoconus nodules and other irregular surfaces); and (4) corneal scars and opacities (post-traumatic, post-surgical, post-infectious and secondary to pathology).

On March 21, 1994, the Ophthalmic Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended conditional approval of the application. The concerns of the panel have been adequately addressed by Summit Technology, Inc., in subsequent submissions to FDA. On March 10, 1995, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH.

A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document.

Opportunity for Administrative Review

Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under § 10.33(b) (21 CFR 10.33(b)). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the **Federal Register**. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details.

Petitioners may, at any time on or before August 7, 1995, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h) (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).

Dated: June 26, 1995.

Joseph A. Levitt,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.

[FR Doc. 95–16624 Filed 7–5–95; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration

Proposed Data Collections Available for Public Comment and Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Health Resources and Services Administration (HRSA) will publish periodic summaries of proposed projects. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, call the HRSA Reports Clearance Officer on (301) 443–1129.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Projects: 1. Evaluation of the Effectiveness and Impact of Community Health Centers—New—A mail survey will be conducted of fifty community health centers (CHCs) to collect information on characteristics of health centers (e.g., patients, services, staffing, financing and participation in managed care) during 1992. The survey is one component of an evaluation of community health centers that examines utilization and expenditures among Medicaid CHC users and non-users, using a sample of 50 health centers in 10 states. The survey will collect data that supplement information already available from health center annual reports, reviews and grant applications. Together with the secondary data, the survey results provide the basis for characterizing attributes of the CHC delivery system and examining whether features of the CHC delivery model assist in explaining observed differentials in use and expenditures among CHC users. The survey will be mailed to CHC Executive Directors, who are expected to delegate portions of the questionnaire to staff for completion. Burden estimates are as follows:

Number of respondents	Number of responses per respondent	Average burden per response (hours)
50 CHCs	1	10–14 hours*

*Burden estimate is based on previous experience with similar surveys of CHCs. Estimates will be refined based on pilot test.

2. Data Collection and Reporting Requirements for Healthy Start—Extension and Revision—Patient records and aggregate data are being collected from Healthy Start grantees in order to evaluate the overall effectiveness of the initiative and the value of specific interventions for varying groups of target women. A number of minor revisions have been proposed based on consultations with grantees regarding availability and utility of the data. Burden estimates are as follows:

Number of respondents	Responses per respondent	Average burden per response (hours)
Patient Data	1	200
Midyear Reports	1	5
Aggregate Reports	1	40

Send comments to Patricia Royston, HRSA Reports Clearance Officer, Room 14–36, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857. Written comments should be received within 60 days of this notice.

Dated: June 30, 1995.

J. Henry Montes,

Associate Administrator for Policy Coordination.

[FR Doc. 95–16523 Filed 7–5–95; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Assistant Secretary for Public and Indian Housing

[Docket No. N–95–3756; FR–3841–N–02]

NOFA for Public and Indian Housing Youth Development Initiative Under the Family Investment Centers Program: Amendment

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Amendment of NOFA.

SUMMARY: This Notice amends a NOFA that was published in the **Federal Register** on May 30, 1995, to announce a set-aside HOPE in Youth Demonstration Program involving two housing agencies in Los Angeles, California. As a result, the total remaining funds to be awarded under the criteria set out in the NOFA is $9 million. In addition, this amendment corrects the address of HUD's Philadelphia, Pennsylvania, field office, as listed in the NOFA.

FOR FURTHER INFORMATION CONTACT: Bertha M. Jones, Office of Community Relations and Involvement (OCRI), Room 4112, Department of Housing and Urban Development, 451 Seventh Street, S.W., Washington, DC 20410; telephone numbers: (202) 708–4214; Hearing-or speech-impaired persons may use the Telecommunications Devises for the Deaf (TDD) by contacting the Federal Information Relay Services on 1–800–877–TDDY (1–800–877–8339) or 202–708–9300 (not a toll-free number) for information on the program.

SUPPLEMENTARY INFORMATION: Accordingly, FR Doc. 95–13094, the NOFA for Youth Development Initiative Under Public and Indian Housing Family Investment Centers, published at 60 FR 28304 (May 30, 1995), is amended as follows:

1. On page 28304, in the first column, the first paragraph under the Summary, the NOFA is revised by adding a new sentence after the first sentence, to read as follows:

* * * Of the up to $10 million in funding for Fiscal Year 1995, $1 million has been set-aside for a HOPE in Youth Demonstration Program, leaving up to $9 million to be awarded under this NOFA.

* * * * *

2. On page 28304, in the second column, the first paragraph in Section I.B, Allocation Amounts, is revised by adding two sentences at the end of the paragraph, to read as follows:

* * * Of the up to $10 million in funding announced for Fiscal Year 1995, $1 million has been set-aside for a HOPE in Youth Demonstration Program, leaving up to $9 million to be awarded under this NOFA. A notice describing the HOPE in Youth Demonstration Program and soliciting public comments on the demonstration is expected to be published soon in the **Federal Register**.

* * * * *

3. On page 28315, in the first column, under the heading for the ''HUD—Mid-Atlantic Area—Pennsylvania, Washington, DC, Maryland, Delaware, Virginia, West Virginia'' in the Appendix the street address for the Public Housing Division of the Philadelphia, Pennsylvania HUD Field